Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Intraepithelial lymphocytes

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    8 result(s) found for: Intraepithelial lymphocytes. Displaying page 1 of 1.
    EudraCT Number: 2007-005230-37 Sponsor Protocol Number: HPV01/01 Start Date*: 2008-04-02
    Sponsor Name:Leiden University Medical Center
    Full Title: Randomised Controlled Study on the Effects of Imiquimod, a TLR 7 Activating Agent, on the HPV16-Specific Immune Response Following HPV16 E6/E7 Synthetic Long Peptides Vaccination in Women with HPV1...
    Medical condition: Adult female patients, with histological evidence of Vulvar intraepithelial neoplasia (VIN) grade III lesions of the squamous cell type, positive for HPV (Human Papilloma Virus)16.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056574 Vulval intraepithelial neoplasia LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2011-002035-26 Sponsor Protocol Number: 115411 Start Date*: 2011-10-21
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase IIIb observer-blind, randomized, multicentre primary immunization study to evaluate the immunogenicity and safety of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine and Merck's Quadrivalent ...
    Medical condition: Cervarix is indicated in females from 10 years of age onwards for the prevention of persistent infection, premalignant cervical lesions and cervical cancer (squamous-cell carcinoma and adenocarcino...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10033723 Papilloma viral infection NOS LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008229 Cervical cancer LLT
    14.0 10038604 - Reproductive system and breast disorders 10056576 Cervical intraepithelial neoplasia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Female
    Trial protocol: FR (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004063-36 Sponsor Protocol Number: CELIM-RCD-002 Start Date*: 2016-02-22
    Sponsor Name:Celimmune LLC
    Full Title: A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients with Type II Refractory Celiac Disease, an In Situ Sm...
    Medical condition: Type II Refractory Celiac Disease (RCD-II)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) NL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-003125-21 Sponsor Protocol Number: P170915J Start Date*: 2020-03-23
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: EFFECT OF INTRAVENOUS IRON SUPPLEMENTATION ON CELIAC DISEASE REMISSION IN PATIENTS WITH IRON DEFICIENCY AND INTESTINAL VILLOUS ATROPHY: A RANDOMIZED TRIAL
    Medical condition: Celiac patients with iron deficiency and intestinal villous atrophy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-012221-10 Sponsor Protocol Number: ALV003-0921 Start Date*: 2009-07-21
    Sponsor Name:Alvine Pharmaceuticals, Inc.
    Full Title: A Phase 2a, Double Blind, Placebo Controlled Study of the Efficacy, Safety and Tolerability of 6-week Treatment With ALV003 In Patients With Well-Controlled Celiac Disease
    Medical condition: Celiac Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007864 Celiac disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005994-36 Sponsor Protocol Number: BUG-1/LMC Start Date*: 2010-01-27
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, double-dummy, randomised, placebo-controlled, multi-centre phase III study on the efficacy and tolerability of a 8-week treatment with 9 mg budesonide vs. 3 g mesalazine vs. placebo i...
    Medical condition: Induction of remission in lymphocytic colitis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004856 10025268 Lymphocytic colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) SE (Completed) BE (Completed) DK (Completed) CZ (Completed) LT (Completed) ES (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-003660-31 Sponsor Protocol Number: ALV003-1221 Start Date*: 2013-11-27
    Sponsor Name:Alvine Pharmaceuticals, Inc.
    Full Title: A Phase 2b, Randomized, Double-Blind, PLacebo-Controlled Dose-Ranging Study of the Efficacy and Safety of ALV003 Treatment in Symptomatic Celiac Disease Patients Maintained on a Gluten-Free Diet
    Medical condition: Celiac Disease
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004856 10007864 Celiac disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed) IE (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2013-001912-31 Sponsor Protocol Number: BUG-3/MIC Start Date*: 2014-02-19
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Randomised, double-blind, placebo-controlled, multi-centre trial on the efficacy and safety of budesonide for induction of remission in incomplete microscopic colitis
    Medical condition: Patients with active incomplete microscopic colitis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10017947 - Gastrointestinal disorders 10056979 Colitis microscopic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) ES (Completed) SE (Completed) NL (Prematurely Ended) DK (Completed) LT (Completed) PT (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 18 10:09:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA